Bone densitometry firm Lunar of Madison, WI, released financial results for its fourth quarter (end-June) that showed a respectable 9% increase in revenue. The company appears to have enjoyed a slightly better quarter than competitor Hologic, which saw
Bone densitometry firm Lunar of Madison, WI, released financial results for its fourth quarter (end-June) that showed a respectable 9% increase in revenue. The company appears to have enjoyed a slightly better quarter than competitor Hologic, which saw its revenues climb only 3%.
For the quarter, Lunar had revenues of $22.2 million, compared with $20.3 million in the fourth quarter of 1996. The company enjoyed net income of $3.6 million, compared with a profit of $3.1 million in the same period of 1996. For the year, Lunar had sales of $81.5 million, up 22% compared with $66.9 million in 1996. The company finished fiscal 1997 with a net profit of $14.3 million, compared with net income of $9.2 million the year before.
Lunar president Dr. Richard Mazess reported that the company is enjoying continued strong demand for its DPIX-IQ x-ray densitometer, particularly in the U.S. The company said that sales of its Artoscan MRI systems and Orca mini-C-arms increased as well, with revenues from both these product lines climbing 42% to $9.1 million for the year.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.